Maryland News Desk

“Metastatic Melanoma Pipeline Insight, 2026“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Metastatic Melanoma Market.

The Metastatic Melanoma Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Metastatic Melanoma Pipeline Report:

• Companies across the globe are diligently working toward developing novel Metastatic Melanoma treatment therapies with a considerable amount of success over the years.

• Metastatic Melanoma companies working in the treatment market are Immatics Biotechnologies, Replimune and Bristol Myers Squibb, Philogen, TILT Biotherapeutics, AiVita Biomedical, Immuneering Corporation, Ultimovacs ASA, MPyxis Oncology, Evaxion Biotech, HUYABIO International, LLC., IO Biotech, Regeneron Pharmaceuticals, IO Biotech, Checkmate Pharmaceuticals, Evaxion Biosciences, Apexigen, Inc., Biocad, Zucero Therapeutics, Karyopharm Therapeutics, Bristol-Myers Squibb, Viralytics, Nykode Therapeutics, and others, are developing therapies for the Metastatic Melanoma treatment

• Emerging Metastatic Melanoma therapies in the different phases of clinical trials are- IMA203, RP1 (vusolimogene oderparepvec) plus nivolumab, Nidlegy, TILT 123, AV-MEL-1, IMM-1-104, UV1, APX005, EVX 01, HBI-8000, IO102-IO103, Fianlimab, IO102-IO103, CMP-001, EVX-01, APX005M, BCD-217, Pixatimod, Selinexor, Relatlimab, V937, VB10.NEO, and others are expected to have a significant impact on the Metastatic Melanoma market in the coming years.

• In October 2026, Faron Pharmaceuticals announced that the final overall survival results from the metastatic melanoma cohort of its Phase I/II MATINS study (NCT03733990) had been accepted for presentation at ESMO 2026. The trial investigated bexmarilimab, an investigational macrophage checkpoint inhibitor, as a monotherapy in 25 patients with metastatic melanoma who had developed resistance to checkpoint inhibitor therapy. The results are expected to provide further clinical support for the ongoing Phase I/II BLAZE trial, which is assessing bexmarilimab in combination with nivolumab in patients with metastatic melanoma and non-small cell lung cancer (NSCLC) who have progressed following anti-PD-1 treatment. The first patient in the BLAZE trial received treatment on October 1, 2026.

• In August 2026, The U.S. FDA granted accelerated approval to Replimune’s Tudriqev (vusolimogene oderparepvec-wtpg), an investigational genetically engineered oncolytic viral therapy, in combination with nivolumab for adults with unresectable advanced cutaneous melanoma whose disease has progressed following treatment with a PD-1-blocking antibody-based regimen. The approval was based on clinical findings showing an objective response rate of 24% among evaluable patients, with a median duration of response of 14.1 months. The therapy is designed to selectively target and destroy cancer cells while activating an antitumor immune response. Continued approval is contingent upon confirmatory clinical evidence from the Phase III IGNYTE-3 trial.

• In July 2026, the FDA’s Cellular, Tissue, and Gene Therapies Advisory Committee voted 10–3 in favour of the clinical efficacy evidence supporting RP1 (vusolimogene oderparepvec) in combination with nivolumab for patients with advanced melanoma who experienced disease progression following anti-PD-1 therapy. The committee considered evidence from the IGNYTE clinical trial, including durable responses in heavily pretreated patients. This regulatory milestone preceded the FDA’s accelerated approval of the combination in August 2026.

• In July 2026, clinical trial findings reported for advanced melanoma indicated that the combination of tucidinostat, an HDAC inhibitor, and nivolumab, an anti-PD-1 immunotherapy, improved progression-free survival compared with nivolumab alone in previously untreated advanced melanoma patients. The findings highlight the potential of combining epigenetic modulation with immune checkpoint inhibition to enhance antitumor activity. The combination remains investigational and requires further clinical evaluation.

• In June 2026, the US FDA accepted Replimune’s Biologics License Application (BLA) resubmission for RP1 (vusolimogene oderparepvec), an investigational oncolytic immunotherapy, in combination with nivolumab for patients with advanced melanoma. The application was classified as a complete Class 1 response, with an FDA action date of August 2, 2026. The therapy is designed to selectively target tumor cells and stimulate antitumor immunity. The regulatory development followed two previous complete response letters and was supported by clinical findings from the IGNYTE study.

• In May 2025, Immatics announced the presentation of updated data from its ongoing Phase Ib trial assessing IMA203 in heavily pretreated metastatic melanoma patients. The company also shared information from a trial-in-progress poster on SUPRAME, the Phase III study evaluating IMA203 in patients with unresectable or metastatic cutaneous melanoma who have previously received checkpoint inhibitor therapy, at ASCO 2025.

Metastatic Melanoma Overview

Metastatic Melanoma is an advanced stage of melanoma, a type of skin cancer, where cancer cells spread beyond the original tumor site to distant organs such as the lungs, liver, brain, or bones. It occurs when melanoma cells invade the bloodstream or lymphatic system, leading to secondary tumors. Metastatic melanoma is highly aggressive but can be treated with targeted therapies (BRAF and MEK inhibitors), immunotherapy (checkpoint inhibitors like nivolumab and pembrolizumab), chemotherapy, or radiation therapy. Early detection and advanced treatments have improved survival rates and patient outcomes.

Get a Free Sample PDF Report to know more about Metastatic Melanoma Pipeline Therapeutic Assessment:

https://www.delveinsight.com/report-store/metastatic-melanoma-pipeline-insight

Emerging Metastatic Melanoma Drugs Under Different Phases of Clinical Development Include:

• IMA203: Immatics Biotechnologies

• RP1 (vusolimogene oderparepvec) plus nivolumab: Replimune and Bristol Myers Squibb

• Nidlegy: Philogen

• TILT 123: TILT Biotherapeutics

• AV-MEL-1: AiVita Biomedical

• IMM-1-104: Immuneering Corporation

• UV1: Ultimovacs ASA

• APX005: MPyxis Oncology

• EVX 01: Evaxion Biotech

• HBI-8000: HUYABIO International, LLC.

• IO102-IO103: IO Biotech

• Fianlimab: Regeneron Pharmaceuticals

Metastatic Melanoma Route of Administration

Metastatic Melanoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

• Intra-articular

• Intraocular

• Intrathecal

• Intravenous

• Ophthalmic

• Oral

• Parenteral

• Subcutaneous

• Topical

• Transdermal

Metastatic Melanoma Molecule Type

Metastatic Melanoma Products have been categorized under various Molecule types, such as

• Oligonucleotide

• Peptide

• Small molecule

Metastatic Melanoma Pipeline Therapeutics Assessment

• Metastatic Melanoma Assessment by Product Type

• Metastatic Melanoma By Stage and Product Type

• Metastatic Melanoma Assessment by Route of Administration

• Metastatic Melanoma By Stage and Route of Administration

• Metastatic Melanoma Assessment by Molecule Type

• Metastatic Melanoma by Stage and Molecule Type

DelveInsight’s Metastatic Melanoma Report covers around 75+ products under different phases of clinical development like

• Late-stage products (Phase III)

• Mid-stage products (Phase II)

• Early-stage product (Phase I)

• Pre-clinical and Discovery stage candidates

• Discontinued & Inactive candidates

• Route of Administration

Further Metastatic Melanoma product details are provided in the report. Download the Metastatic Melanoma pipeline report to learn more about the emerging Metastatic Melanoma therapies

Some of the key companies in the Metastatic Melanoma Therapeutics Market include:

Key companies developing therapies for Metastatic Melanoma are – Evaxion Biotech, InxMed, AiVita Biomedical, Iovance Biotherapeutics, Viralytics, Merck & Co., Neon Therapeutics, BioNTech, Bristol-Myers Squibb, Ono Pharmaceuticals, Cytovation AS, Biocad, Apexigen, Checkmate Pharmaceutical, Nektar therapeutics, HUYABIO International, LLC., IO Biotech, Bristol Myers Squibb, Karyopharm Therapeutics, Zucero Therapeutics, GlaxoSmithKline, Tesaro, Inc., Ultimovacs ASA, Eucure (Beijing) Biopharma Co., Ltd, Incyte Corporation, Philogen S.p.A., Ascentage Pharma, Exelixis/Ipsen, NovoCure Ltd., Hoffman-La-Roche, Provectus Biopharmaceuticals, BerGenBio ASA, Idera Pharmaceuticals, Celgene Corporation, Novartis, Taizhou Hanzhong biomedical co. LTD, Scancell Ltd, BioMed Valley Discoveries, Inc., Nykode Therapeutics, Sapience Therapeutics, BeiGene, Immunocore, Achilles Therapeutics UK Limited, Vanquish Oncology, Syntrix Biosystems, Inc., TILT Biotherapeutics, PrimeVax Immuno-Oncology Inc., Celldex Therapeutics, Taiga Biotechnologies, Inc., Galectin Therapeutics Inc, Foghorn Therapeutics Inc., TriSalus Life Sciences, Inc., Miltenyi Biomedicine GmbH, CytomX Therapeutics, Inc., Seagen Inc., Immutep, Regeneron pharmaceuticals, Adaptimmune, IDEAYA Biosciences, PokeAcell, Ultimovacs ASA, Verastem, Inc., PACT Pharma, Actuate Therapeutics, Inc., and others.

Metastatic Melanoma Pipeline Analysis:

The Metastatic Melanoma pipeline report provides insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Metastatic Melanoma with aggregate therapies developed by each company for the same.

• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Metastatic Melanoma Treatment.

• Metastatic Melanoma key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

• Metastatic Melanoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Metastatic Melanoma market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Metastatic Melanoma drugs and therapies

Metastatic Melanoma Pipeline Market Drivers

• Improving Healthcare Infrastructure, emergence of effective immune therapies are some of the important factors that are fueling the Metastatic Melanoma Market.

Metastatic Melanoma Pipeline Market Barriers

• However, lack Of Cost-Effective Treatment, side effects associated with the treatment and other factors are creating obstacles in the Metastatic Melanoma Market growth.

Scope of Metastatic Melanoma Pipeline Drug Insight

• Coverage: Global

• Key Metastatic Melanoma Companies: Immatics Biotechnologies, Replimune and Bristol Myers Squibb, Philogen, TILT Biotherapeutics, AiVita Biomedical, Immuneering Corporation, Ultimovacs ASA, MPyxis Oncology, Evaxion Biotech, HUYABIO International, LLC., IO Biotech, Regeneron Pharmaceuticals, IO Biotech, Checkmate Pharmaceuticals, Evaxion Biosciences, Apexigen, Inc., Biocad, Zucero Therapeutics, Karyopharm Therapeutics, Bristol-Myers Squibb, Viralytics, Nykode Therapeutics, and others

• Key Metastatic Melanoma Therapies: IMA203, RP1 (vusolimogene oderparepvec) plus nivolumab, Nidlegy, TILT 123, AV-MEL-1, IMM-1-104, UV1, APX005, EVX 01, HBI-8000, IO102-IO103, Fianlimab, IO102-IO103, CMP-001, EVX-01, APX005M, BCD-217, Pixatimod, Selinexor, Relatlimab, V937, VB10.NEO, and others

• Metastatic Melanoma Therapeutic Assessment: Metastatic Melanoma current marketed and Metastatic Melanoma emerging therapies

• Metastatic Melanoma Market Dynamics: Metastatic Melanoma market drivers and Metastatic Melanoma market barriers

Request for Sample PDF Report for Metastatic Melanoma Pipeline Assessment and clinical trials

Table of Contents

1. Metastatic Melanoma Report Introduction

2. Metastatic Melanoma Executive Summary

3. Metastatic Melanoma Overview

4. Metastatic Melanoma- Analytical Perspective In-depth Commercial Assessment

5. Metastatic Melanoma Pipeline Therapeutics

6. Metastatic Melanoma Late Stage Products (Phase II/III)

7. Metastatic Melanoma Mid Stage Products (Phase II)

8. Metastatic Melanoma Early Stage Products (Phase I)

9. Metastatic Melanoma Preclinical Stage Products

10. Metastatic Melanoma Therapeutics Assessment

11. Metastatic Melanoma Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Metastatic Melanoma Key Companies

14. Metastatic Melanoma Key Products

15. Metastatic Melanoma Unmet Needs

16 . Metastatic Melanoma Market Drivers and Barriers

17. Metastatic Melanoma Future Perspectives and Conclusion

18. Metastatic Melanoma Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV 89107
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services